Kopran Limited
Kopran Ltd. is an integrated Pharmaceutical Company, committed to manufacture and supply International Quality Formulations and Active Pharmaceutical Ingredients worldwide.
What Kopran files
- Others45
- Board Meeting9
- PPTs6
- JV/Acquisition6
- Investor Meet6
- Important5
Kopran's promoters have finalized a Family Settlement, resolving long-standing shareholding and management disputes. This agreement consolidates the company's control under one family branch, aiming for streamlined governance and operational clarity moving forward.
Kopran Ltd. has announced a board meeting. In the latest financial results, the company's consolidated revenue from operations for the quarter ending December 31, 2024, surged to ₹16,624.29 crore, reflecting a solid year-on-year growth of approximately 4.6%. This growth can be attributed to increased demand for pharmaceuticals and effective market...
**Financial Highlights:** Kopran reported a revenue from operations of ₹15,156 lakh for Q2 FY 2024-25, showing an increase from ₹13,944 lakh in Q1 FY 2024-25 but a slight decline compared to ₹15,259 lakh in Q2 FY 2023-24. The company’s EBITDA was ₹1,474 lakh, resulting in an EBITDA margin of 9.72%....
Kopran Ltd. has reported consolidated revenue of ₹15,156.19 cr for the quarter, reflecting a growth of 3.44% quarter-over-quarter and a slight decline of 0.68% year-over-year. This performance was bolstered by increased demand and effective market expansion strategies. The consolidated net profit stood at ₹738.41 cr, down 33.76% year-over-year, leading to...
Kopran Ltd. has approved the allotment of 38,800 equity shares under its Employee Stock Option Plan 2023. The shares have a face value of Rs. 10 each, with an exercise price of Rs. 179 per share. Following this allotment, the paid-up equity share capital of the company has increased to...